• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr
J-GLOBAL ID:201901011715996968   Update date: Sep. 15, 2024

Masuda Muneyuki

Masuda Muneyuki
Clips
Affiliation and department:
Job title: Deputy Director of the Center
Research field  (1): Otorhinolaryngology
Research keywords  (4): epigenetics ,  molecular biology ,  head and neck surgery ,  head and neck cancer
Research theme for competitive and other funds  (13):
  • 2022 - 2027 側頭骨扁平上皮癌の悪性度を決定するエピジェネティックな腫瘍制御機構の解明
  • 2021 - 2024 Roles of tissue degenerative tansscriptional reprogramming in the evolution of head and neck cancer
  • 2021 - 2024 頭頸部・食道の損傷・修復異常に着目した発癌・進展の機序解明と個別化治療戦略の確立
  • 2018 - 2021 Molecular mechanism of carcinogenesis of head and neck and esophagus induced by cigarette smoking and alcohol drinking: Aiming to establishment of personalized treatment strategy
  • 2016 - 2019 Epigenetic reprogramming in head and neck cancer
Show all
Papers (144):
  • Mioko Matsuo, Muneyuki Masuda, Moriyasu Yamauchi, Kazuki Hashimoto, Ryunosuke Kogo, Masanobu Sato, Shogo Masuda, Takashi Nakagawa. Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation. Cancers. 2024. 16. 14
  • Hirofumi Omori, Takahiro Wakasaki, Takahiro Hongo, Fumihide Rikimaru, Satoshi Toh, Yuichiro Higaki, Muneyuki Masuda. Acquired tracheobronchomalacia developed following voice prosthesis implantation. Auris, nasus, larynx. 2024. 51. 3. 433-436
  • Takahiro WakasakiI, Tomomi Manako, Ryuji YasumatsuI, Hirotaka Hara, Satoshi Toh, Muneyuki Masuda, Moriyasu YamauchiID, Yuichiro Kuratomi, Emi Nishimura, Toranoshin Takeuchi, et al. Erratum: Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study (PloS one (2022) 17 7 (e0271907)). PloS one. 2024. 19. 5. e0303720
  • 益田 宗幸, 藤 賢史, 佐藤 晋彰, 松尾 未央子, 菅澤 正, 山崎 惠介, 植木 雄志, 中島 寅彦, 瓜生 英興, 小野 剛治, et al. 頭頸部癌患者血漿exosome mRNA網羅的解析によるニボルマブ治療効果予測因子の同定. 日本癌治療学会学術集会抄録集. 2023. 61回. SP-4
  • Kuniaki Sato, Satoshi Toh, Taku Murakami, Takafumi Nakano, Takahiro Hongo, Mioko Matsuo, Kazuki Hashimoto, Masashi Sugasawa, Keisuke Yamasaki, Yushi Ueki, et al. Prospective exploration of a prognostic biomarker of nivolumab for head and neck cancer patients (BIONEXT). 2023
more...
MISC (221):
more...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page